{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:53:01Z","timestamp":1772891581485,"version":"3.50.1"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[1997,9,1]],"date-time":"1997-09-01T00:00:00Z","timestamp":873072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Diagn Lab Immunol"],"published-print":{"date-parts":[[1997,9]]},"abstract":"<jats:p>Thyrotoxic patients exhibit increased levels of immune activation molecules (soluble interleukin-2 receptor [sIL-2R], intercellular adhesion molecule-1 [ICAM-1], and endothelial-leukocyte adhesion molecule-1 [ELAM-1]) in serum, although the clinical significance of these measurements remains unclear. In a randomized 4-week study, we have recently shown that in the treatment of hyperthyroidism, the combination of cholestyramine and methimazole (MMI) resulted in faster lowering of serum thyroid-hormone levels than did MMI alone. Stored serial serum samples from patients participating in this randomized treatment trial were analyzed for sIL-2R, soluble ICAM-1 (sICAM-1), and soluble ELAM-1 (sELAM-1). The levels of all three molecules were elevated in patients with hyperthyroidism. Although the levels of sICAM-1 and sELAM-1 remained elevated through the 4-week follow-up period in both groups of patients, the sIL-2R levels (normal levels, 1.0 to 4.2 ng\/ml) decreased significantly in the 10 patients who received cholestyramine in addition to MMI (week 0, 14.2 +\/- 1.5 ng\/ml; week 2, 10.8 +\/- 1.2 ng\/ml; week 4, 8.9 +\/- 1.5 ng\/ml). In eight patients who received MMI alone, sIL-2R decreased less rapidly (week 0, 12.3 +\/- 1.4 ng\/ml; week 2, 12.3 +\/- 1.3 ng\/ml; week 4, 10.9 +\/- 1.3 ng\/ml). sICAM-1 and sELAM-1 were elevated at baseline but did not decrease during therapy. In the former group, free thyroxine and free triiodothyronine decreased faster. These data show that levels of sIL-2R in serum, but not those of sICAM-1 and sELAM-1, may be of clinical use in the early follow-up evaluation of medically treated patients.<\/jats:p>","DOI":"10.1128\/cdli.4.5.583-586.1997","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T18:40:05Z","timestamp":1578336005000},"page":"583-586","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis"],"prefix":"10.1128","volume":"4","author":[{"given":"R C","family":"Smallridge","sequence":"first","affiliation":[{"name":"Endocrinology Division, Mayo Clinic Jacksonville, Florida 32224, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G C","family":"Tsokos","sequence":"additional","affiliation":[{"name":"Endocrinology Division, Mayo Clinic Jacksonville, Florida 32224, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K D","family":"Burman","sequence":"additional","affiliation":[{"name":"Endocrinology Division, Mayo Clinic Jacksonville, Florida 32224, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Porter","sequence":"additional","affiliation":[{"name":"Endocrinology Division, Mayo Clinic Jacksonville, Florida 32224, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Cranston","sequence":"additional","affiliation":[{"name":"Endocrinology Division, Mayo Clinic Jacksonville, Florida 32224, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P P","family":"Sfikakis","sequence":"additional","affiliation":[{"name":"Endocrinology Division, Mayo Clinic Jacksonville, Florida 32224, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B L","family":"Solomon","sequence":"additional","affiliation":[{"name":"Endocrinology Division, Mayo Clinic Jacksonville, Florida 32224, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Clinical Diagnostic Laboratory Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/cdli.4.5.583-586.1997","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/cdli.4.5.583-586.1997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T07:27:48Z","timestamp":1645601268000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/cdli.4.5.583-586.1997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,9]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1997,9]]}},"alternative-id":["10.1128\/cdli.4.5.583-586.1997"],"URL":"https:\/\/doi.org\/10.1128\/cdli.4.5.583-586.1997","relation":{},"ISSN":["1071-412X","1098-6588"],"issn-type":[{"value":"1071-412X","type":"print"},{"value":"1098-6588","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,9]]},"assertion":[{"value":"1997-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}